December 11, 2025

New combination treatment improves multiple myeloma outcomes – University of Cincinnati

December 9, 2025

ASH Annual Meeting 2025 Day 3: Novel Antibody Therapies for High-Risk and Relapsed/Refractory Disease

For the last day of ASH, we’re taking a final look at some of the most exciting findings shared during Sunday’s sessions as well as late-breaking abstracts from this morning that highlight where myeloma research is headed next. Whether by investigating new regimens with already-approved treatments, or by developing unique, novel immunotherapies, the studies featured […]

December 9, 2025

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

New England Journal of Medicine, Ahead of Print.

December 8, 2025

ASH Annual Meeting 2025 Day 2: New Data Show Lasting Responses with CAR T and Oral Therapies

Today’s update from the 2025 ASH Annual Meeting highlights new and existing therapies that could improve care for patients at all stages of multiple myeloma. Read the key takeaways below, and be sure to catch up on the first day. For a deeper dive into the most important findings from ASH, join us for our […]

December 8, 2025

Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts – Memorial Sloan Kettering Cancer Center